Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species

Wound Rinse Removes Bacteria and Biofilms and Enhances Healing

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Claremont CA (PRWEB) May 05, 2013

Removing embedded bacteria from biofilms in wounds remains a challenge to doctors and caregivers. Likewise, veterinarians face similar challenges treating their zoo patients. Synedgen will report compelling data on new treatments against wound biofilms at a poster session at the 113th General Meeting of the American Society for Microbiology (asm2013) on May 18-21, 2013, at the Colorado Convention Center in Denver Colorado.

The poster, Antibacterial and Wound Healing Enhancement of PAAG in Minor Species, highlights the antibacterial and biofilm-reducing activity of Synedgen’s Synoplex® rinse. Data will be presented for efficacy against bacteria from elephant wounds and for Klebsiella pneumoniae biofilms. Data from additional collaborative studies evaluating Synoplex in the treatment of chronic elephant and rhinoceros wounds, including foot-disease, pressure ulcers, and infected glands that were not responding well to conventional treatment will also be presented. Synoplex is approved for marketing by the FDA as a treatment for wounds in elephants and rhinoceros.

Bacteria isolated from elephant wounds were all reduced more than 1000 fold after 1-hour treatment with Synoplex. K. pneumonia biofilms were reduced by more than 1000 fold after 5-hour treatment. Epithelial cells, which are responsible for the initial stages of regeneration of tissue, grew to cover at least twice more surface area than other wound treatments and control. Treated minor species showed significant improvement in wound healing and successful resolution of most wounds.
Synedgen’s VP of Research Stacy Townsend PhD will present the results on Tuesday May 21, 2013 at 1:00 PM - 2:45 PM at Poster board # 2194.

“As demonstrated by these studies, Synoplex provides a highly effective prophylactic and therapeutic treatment for controlling and preventing bacterial biofilms associated with chronic and acute dermal wounds including foot disease in minor species,” remarked Townsend. “The non-toxic nature of Synoplex is also beneficial in a large animal setting.”

Synoplex is available directly from Synedgen. For pricing and ordering information, please contact Synedgen at info(at)synedgen(dot)com.

About Synedgen

Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.

Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com.


Contact